Nonfatal StrokeCT-PLAQUENCT07212751
Coronary CT Angiogram - Prognostic Value of Adverse Plaque Features in Guiding Treatment (CT-PLAQUE)
An observational study of Nonfatal Stroke and Nonfatal Myocardial Infarction, run by The University of Hong Kong at 1 site in Hong Kong.
Trial summary
The study aims at determining if the presence of adverse plaque features identified from the CT angiogram can help determine prognosis and guide treatment options. Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Nonfatal Stroke, Nonfatal Myocardial Infarction, Cardiovascular Death
- What is being tested?
- CTCA
- How many people
- 22,000 participants
- Where
- 1 siteHong Kong
- Study dates
- 29 Jan 2020to 31 Dec 2027
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- Adult, Older adult
Study population: 28000
Who may be able to join
- Patient who is ≥ 18 years old presented with chest pain and has undergone CTA between 01-Jan-2012 and 31-Dec-2022 before treatment
- If multiple CTAs are taken, the most updated one before treatment commencement will be chosen.
Who cannot join
- Patient who did not undergo cardiac CT scan due to inability to undergo cardiac CT scanning, kidney failure (serum creatinine >250 μmol/L or estimated glomerular filtration rate <30 mL/min), major allergy to contrast.
Trial locations and contacts
1 site in 1 country.
About this study
The study aims at determining if the presence of adverse plaque features identified from the CT angiogram can help determine prognosis and guide treatment options.
- Conditions
- Nonfatal Stroke, Nonfatal Myocardial Infarction, Cardiovascular Death, All-cause Death, Stroke (Subacute), CT Plaque
- Being tested
- CTCA
- Keywords
- CTCA, CT, Coronary CT, Calcium Score, Plaque, Coronary Artery Disease, CAD, Chest pain
- Medical subject headings
- Stroke, Plaque, Amyloid, Coronary Artery Disease, Chest Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CTCADiagnostic test
Patient who is ≥ 18 years old presented with chest pain and has undergone CTA between 01-Jan-2012 and 31-Dec-2022 before treatment
- If multiple CTAs are taken, the most updated one before treatment commencement will be chosen.
| Study group | Role | What they receive |
|---|---|---|
| Patient who is ≥ 18 years old presented with chest pain and has undergone CTA before treatment | Not described Receives: Diagnostic Test: CTCA |
What is being measured
The primary outcome is the main question the study is designed to answer.
Nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death and all-cause death
Measured: 5 years after CTCA examinations
Secondary outcomes (4)
Total plaque (mm³) to predict cardiac events
Measured: 5 years after CTCA examinations
Calcified plaque (mm³) to predict cardiac events
Measured: 5 years after CTCA examinations
Non-calcified plaque (mm³) to predict cardiac events
Measured: 5 years after CTCA examinations
CT-FFR to predict cardiac events
Measured: 5 years after CTCA examinations
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Oct 2025
- Study start29 Jan 2020
- Primary completion30 Jun 2026 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Nonfatal StrokeStudies of the same condition, open and under way.
- More trials run by The University of Hong KongThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case crossover
- Time perspective
- Cross-sectional
- Enrolment
- 22,000 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- The University of Hong Kong
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07212751
- Sponsor's protocol ID
- UW20-057
- Acronym
- CT-PLAQUE
- Status last verified
- Jun 2025
- First submitted
- 7 Jul 2025
- Last updated
- 19 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Coronary CT Angiogram - Prognostic Value of Adverse Plaque Features in Guiding Treatment (CT-PLAQUE)
- ClinicalTrials.gov ID
- NCT07212751
- Acronym / sponsor ID
- CT-PLAQUE / UW20-057
- Conditions
- Nonfatal Stroke, Nonfatal Myocardial Infarction, Cardiovascular Death, All-cause Death, Stroke (Subacute), CT Plaque
- Keywords
- CTCA, CT, Coronary CT, Calcium Score, Plaque, Coronary Artery Disease, CAD, Chest pain
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 22,000 participants (estimated)
- Lead sponsor
- The University of Hong KongUniversity, hospital or other
- Study start
- 29 Jan 2020 (actual)
- Primary completion
- 30 Jun 2026 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 8 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study aims at determining if the presence of adverse plaque features identified from the CT angiogram can help determine prognosis and guide treatment options.
Study design
- Observational model
- Case crossover
- Time perspective
- Cross-sectional
- Target follow-up
- 5 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patient who is ≥ 18 years old presented with chest pain and has undergone CTA before treatment | – | Diagnostic Test: CTCA |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- 28000
Key inclusion criteria (2 listed)
- Patient who is ≥ 18 years old presented with chest pain and has undergone CTA between 01-Jan-2012 and 31-Dec-2022 before treatment
- If multiple CTAs are taken, the most updated one before treatment commencement will be chosen.
Key exclusion criteria (1 listed)
- Patient who did not undergo cardiac CT scan due to inability to undergo cardiac CT scanning, kidney failure (serum creatinine >250 μmol/L or estimated glomerular filtration rate <30 mL/min), major allergy to contrast.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CTCAPatient who is ≥ 18 years old presented with chest pain and has undergone CTA between 01-Jan-2012 and 31-Dec-2022 before treatment - If multiple CTAs are taken, the most updated one before treatment commencement will be chosen. | Diagnostic test | Patient who is ≥ 18 years old presented with chest pain and has undergone CTA before treatment |
Primary outcome
Nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death and all-cause death
Time frame: 5 years after CTCA examinations
4 secondary outcomes
Total plaque (mm³) to predict cardiac events
Time frame: 5 years after CTCA examinations
Calcified plaque (mm³) to predict cardiac events
Time frame: 5 years after CTCA examinations
Non-calcified plaque (mm³) to predict cardiac events
Time frame: 5 years after CTCA examinations
CT-FFR to predict cardiac events
Time frame: 5 years after CTCA examinations
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 May 2026.
Related trials for Nonfatal Stroke
Active, not recruitingPhase 3
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Nonfatal Stroke and Nonfatal Myocardial Infarction, run by The University of Hong Kong at 1 site in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 19 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death and all-cause death (time frame: 5 years after CTCA examinations). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 May 2026.